These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 7779940

  • 1. Platelet function in patients with lupus anticoagulant and thrombosis.
    Diez-Ewald M, Torres-Guerra E, Vizcaíno G, Arteaga-Vizcaíno M.
    Invest Clin; 1995 Mar; 36(1):13-21. PubMed ID: 7779940
    [Abstract] [Full Text] [Related]

  • 2. Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events.
    Levy Y, Shenkman B, Tamarin I, Pauzner R, Shoenfeld Y, Langevitz P, Savion N, Varon D.
    Arthritis Rheum; 2005 Dec; 52(12):4011-7. PubMed ID: 16320349
    [Abstract] [Full Text] [Related]

  • 3. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus--possible association with thrombotic and thrombocytopenic complications.
    Nojima J, Suehisa E, Kuratsune H, Machii T, Koike T, Kitani T, Kanakura Y, Amino N.
    Thromb Haemost; 1999 Mar; 81(3):436-41. PubMed ID: 10102474
    [Abstract] [Full Text] [Related]

  • 4. [Prevalence of lupus anticoagulant, autoimmune hemolysis, thrombocytopenia and disorders of platelet function in unselected patients with SLE].
    Söhngen D, Specker C, Wehmeier A, Kiefel V, Rathmer L, Söhngen R, Schneider W.
    Beitr Infusionsther; 1992 Mar; 30():469-73. PubMed ID: 1284763
    [Abstract] [Full Text] [Related]

  • 5. Effect of plasma from patients with primary antiphospholipid syndrome on platelet function in a collagen rich perfusion system.
    Reverter JC, Tàssies D, Escolar G, Font J, López Soto A, Ingelmo M, Ordinas A.
    Thromb Haemost; 1995 Jan; 73(1):132-7. PubMed ID: 7740485
    [Abstract] [Full Text] [Related]

  • 6. [Association between antiphospholipid antibodies and arterial or venous thrombosis/thrombocytopenia].
    Nojima J, Suehisa E, Kuratsune H, Amino N.
    Rinsho Byori; 1998 Dec; 46(12):1181-7. PubMed ID: 9916502
    [Abstract] [Full Text] [Related]

  • 7. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, Machin SJ, Brown MM.
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [Abstract] [Full Text] [Related]

  • 8. Platelet function tests using platelet aggregometry: need for repetition of the test for diagnosis of defective platelet function.
    Ghosh K, Nair S, Kulkarni B, Khare A, Shetty S, Mohanty D.
    Platelets; 2003 Sep; 14(6):351-4. PubMed ID: 14602548
    [Abstract] [Full Text] [Related]

  • 9. Platelet aggregation responses vary over a period of time in healthy controls.
    Refaai MA, Frenkel E, Sarode R.
    Platelets; 2010 Sep; 21(6):460-3. PubMed ID: 20536288
    [Abstract] [Full Text] [Related]

  • 10. Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects.
    Vayá A, Santaolaria M, Micó L, Calvo J, Oropesa R, Villa P, Todoli J, Simó M, Corella D, Ricart JM.
    Clin Hemorheol Microcirc; 2008 Sep; 40(2):79-87. PubMed ID: 19029633
    [Abstract] [Full Text] [Related]

  • 11. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH.
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [Abstract] [Full Text] [Related]

  • 12. [Lupus anticoagulants in patients with systemic lupus erythematosus].
    Matsuura Y, Nawata Y, Miike S, Hiraguri M, Kita Y, Kurasawa K, Takabayashi K, Oh H, Iwamoto I, Saito Y.
    Ryumachi; 1996 Feb; 36(1):16-24. PubMed ID: 8711533
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mechanisms underlying increased platelet reactivity in patients with peripheral arterial disease. Preliminary results.
    Reininger CB, Boeger CA, Steckmeier B, Spannagl M, Scweiberer L.
    Int Angiol; 1999 Jun; 18(2):163-70. PubMed ID: 10424375
    [Abstract] [Full Text] [Related]

  • 18. [Incidence of selected antiphospholipid antibodies in a group of patients with systemic lupus erythematosus].
    Fojtík Z, Beránek M, Klabusay M, Korístek Z, Buliková A.
    Vnitr Lek; 2004 Apr; 50(4):267-73. PubMed ID: 15214295
    [Abstract] [Full Text] [Related]

  • 19. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
    Viveros ME, Cabiedes J, Reyes E, Cabral AR.
    Rev Invest Clin; 2005 Apr; 57(4):563-71. PubMed ID: 16315641
    [Abstract] [Full Text] [Related]

  • 20. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
    Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG.
    Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.